Health

New Vaccine From Pfizer Protects Newborn From Severe Illness?

On Tuesday, November 1, Pfizer stated that their RSV vaccine for pregnant women provides at least 6 months of protection against severe illnesses in babies.

The vaccine prevented severe RSV cases in newborns whose mothers were vaccinated by 82% in phase III of a randomized, double-blind, and placebo-controlled research.

For your information, RSV is a common virus that affects the lungs. It makes people like they have a mild cold. Even though most kids and adults who are infected with RSV get better without any major long-term effects, Chang said that the virus could be serious and even kill babies, young kids, and older adults.

This protection lasts from birth until 3 months. Pfizer added that the vaccination was 69% effective at 6 months of age, despite a decrease in protection.

According to Yahoo News, participants in the trial were monitored for six months following vaccination to determine the vaccine’s safety and effectiveness. Moreover, the infants were monitored for at least a year, and more than half were monitored for two years.

“As someone who spent part of their ID training focused on RSV research, this is wonderful news,”

— Dr. Michael Chang, pediatric infectious diseases specialist

Dr. Chang also said that the vaccination might be a “game changer”, but they must consider other things as well. This includes children older than 1 year who have a high disease burden.

RSV mortality is highest among premature infants and newborns who have cyanotic congenital heart disease.  This immunization may not assist these patients, he added.

Chang emphasized that maternal immunization for pertussis (whooping cough) has been utilized successfully in the past. In addition, new results indicate that mothers who get COVIDvaccinations during pregnancy can likewise convey protective antibodies to their infants.

Pfizer’s plan

Pfizer plans to test the vaccine in pregnant women, younger individuals, and elderly people who are at risk for serious infection. In August, the company revealed positive vaccination trial results in older adults.

Pfizer has stated that it intends to submit a licensing application to the FDA before the year’s end. Vaccine distribution is anticipated for late 2023 or early 2024 if it receives regulatory approval.

Source: Yahoo News, NBC News

Adib Mohd

Recent Posts

Year-End Getaways to Indonesia with Deals from RM40 – Discover Hidden Gems Beyond Bali

As the year winds down, Traveloka is helping travelers rediscover Indonesia’s locally loved destinations through… Read More

1 day ago

Le Méridien Kuala Lumpur Unveils “A Timeless Collection” of Mooncakes This Mid-Autumn

This Mid-Autumn Festival, Le Méridien Kuala Lumpur invites guests to celebrate tradition with elegance through… Read More

1 day ago

Google Unveils Pixel 10 Series, Pro Fold, Watch 4 & Buds 2a at Made by Google 2025

Google has just pulled back the curtain on its newest Pixel lineup at the annual… Read More

1 day ago

PayNet & Ant International Expand Partnership to Take DuitNow QR Global

Payments Network Malaysia (PayNet) and Ant International have signed a new Memorandum of Understanding (MoU)… Read More

1 day ago

ZTE & MMU Team Up to Build Malaysia’s Next Wave of ICT Talent

ZTE Corporation has signed a Memorandum of Understanding (MoU) with Multimedia University (MMU), paving the… Read More

1 day ago

Melbourne Beyond the City: Road Trips and Campervan Adventures

Melbourne is famous for its laneways, coffee culture, and buzzing arts scene, but here’s a… Read More

2 days ago

This website uses cookies.